Organs-on-chips will radically change the way and the speed at which drugs can be implemented clinically, not only for general drug development but also for personalised drugs. This is not only key for making drug and cosmetic development test-animal free, but the accuracy and speed with which outcomes can be evaluated will surpass standard cell cultures and laboratory animals that presently capture human physiology and response on drugs imperfectly. Organ-on-chip technology is cutting-edge science, which goes beyond the frontiers of knowledge and requires multidisciplinary collaboration. hDMT, one of the partners of this consortium, has submitted a FET Flagship proposal for this technology with a broad support from European research centres and is actively working with other regenerative medicine proposals to settle a broad EU flagship. Partners are European leaders in their specialist area but their collaboration is essential to realize the potential of this emerging technology.